Drug-related damage of the ageing gastrointestinal tract

Best Practice and Research: Clinical Gastroenterology

Volumn 23, Issue 6, 2009, Pages 849-860

  Sostres, Carlos ^a   Gargallo, Carla ^a   Lanas, Angel ^a  

^a INSTITUTO ARAGONÉS DE CIENCIAS DE LA SALUD   (Spain)

Author keywords

aspirin; elderly; gastrointestinal damage; nonsteroidal antiinflammatory drugs

Indexed keywords

ACECLOFENAC; ACETYLSALICYLIC ACID; ALLOPURINOL; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; CELECOXIB; CLOPIDOGREL; CORTICOSTEROID; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; ETORICOXIB; IBUPROFEN; INDOMETACIN; KETOPROFEN; KETOROLAC; LORNOXICAM; LUMIRACOXIB; MELOXICAM; NAPROXEN; NIMESULIDE; NONSTEROID ANTIINFLAMMATORY AGENT; PIROXICAM; PLACEBO; PROTON PUMP INHIBITOR; ROFECOXIB; SEROTONIN UPTAKE INHIBITOR; TICLOPIDINE; UNINDEXED DRUG; WARFARIN;

ABDOMINAL PAIN; ACUTE CORONARY SYNDROME; AGING; ARTICLE; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; COMORBIDITY; DIARRHEA; DIGESTIVE SYSTEM HEMORRHAGE; DIGESTIVE SYSTEM PERFORATION; DIGESTIVE SYSTEM ULCER; DIVERTICULITIS; DRUG FATALITY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DUODENUM ULCER; DYSPEPSIA; ENTERITIS; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL OBSTRUCTION; GASTROINTESTINAL SYMPTOM; GASTROINTESTINAL TOXICITY; HEARTBURN; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; INTESTINE MUCOSA PERMEABILITY; INTESTINE PERFORATION; LOW DRUG DOSE; MELENA; MONOTHERAPY; NAUSEA; PREVALENCE; RECOMMENDED DRUG DOSE; RECTUM HEMORRHAGE; RHEUMATOID ARTHRITIS; RISK FACTOR; SIDE EFFECT; STOMACH ULCER; ULCER PERFORATION; UPPER GASTROINTESTINAL BLEEDING; UPPER GASTROINTESTINAL TRACT; VOMITING;

AGE FACTORS; AGED; AGED, 80 AND OVER; AGING; ANTI-BACTERIAL AGENTS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ASPIRIN; CYCLOOXYGENASE 2 INHIBITORS; FEMALE; GASTROINTESTINAL DISEASES; GASTROINTESTINAL TRACT; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; MALE; MIDDLE AGED; RISK ASSESSMENT; RISK FACTORS;

EID: 72149130060     PISSN: 15216918     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bpg.2009.10.006     Document Type: Article

References (93)

1. Gray S.L., Sager M., Lestico M.R., et al. Adverse drug events in hospitalized elderly. J Gerontol Med Sci 53A (1998) M59-M63
2. Gurwitz J.H., Field T.S., Harrold L.R., et al. Incidence and preventability of adverse drug events among older persons in the ambulatory setting. JAMA 289 (2003) 1107-1116
3. Pilotto A., Franceschi M., Vitale D., et al. Drug use by the elderly in general practice: effects on upper gastrointestinal symptoms. Eur J Pharmacol 62 (2006) 65-73
4. Jones R. Nonsteroidal anti-inflammatory drug prescribing: past, present, and future. Am J Med 110 (2001) 4S-7S
5. Lapane K.L., Spooner J.J., Mucha L., et al. Effect of nonsteroidal anti-inflammatory drugs use on the rate of gastrointestinal hospitalizations among people living in long-term care. J Am Geriatr Soc 49 (2001) 577-584
6. Pilotto A., Franceschi M., Leandro G., et al., Geriatric Gastroenterology Study Group (Societá Italiana Gerontologia Geriatria). NSAID and aspirin use by the elderly in general practice: effect on gastrointestinal symptoms and therapies. Drugs Aging 20 (2003) 701-710
7. Pilotto A., Franceschi M., Vitale D.F., et al. Upper gastrointestinal symptoms and therapies in elderly out-patients, users of non-selective NSAIDs or coxib. Aliment Pharmacol Ther 22 (2005) 147-155
8. García Rodríguez L.A., and Barreales Tolosa L. Risk of upper gastrointestinal complications among users of traditional NSAIDs and COXIBs in the general population. Gastroenterology 132 2 (2007 Feb) 498-506
9. Laine L., Bombardier C., Hawkey C.J., et al. Stratifying the risk of NSAID-related upper gastrointestinal clinical events: results of a double-blind outcomes study in patients with rheumatoid arthritis. Gastroenterology 123 4 (2002) 1006-1012
10. Silverstein F.E., Graham D.Y., Senior J.R., et al. Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 123 4 (1995) 241-249
11. Brun J., and Jones R. Non-steroidal anti-inflammatory drug-associated dyspepsia: the scale of the problem. Am J Med 110 (2001) 12S-13S
12. Lanas A., and Hunt R. Prevention of anti-inflammatory drug induced gastrointestinal damage: benefits and risks of therapeutic strategies. Ann Med 38 6 (2006) 415-428
13. Kimmey M.B., and Lanas A. Review article: appropriate use of proton pump inhibitors with traditional nonsteroidal anti-inflammatory drugs and COX-2 selective inhibitors. Aliment Pharmacol Ther 19 Suppl. 1 (2004) 60-65
14. De Abajo F.J., and García Rodríguez L.A. Risk of upper gastrointestinal bleeding and perforation associated with low-dose aspirin as plain and enteric-coated formulations. BMC Clin Pharmacol 1 (2001) 1
15. Lanas A., García Rodriguez L.-A., Arroyo M.T., et al. Risk of upper gastrointestinal ulcer bleeding associated with selective COX-2 inhibitors, traditional non-aspirin NSAIDs, aspirin, and combinations. Gut 55 12 (2006 Dec) 1731-1738
16. Ramosekh D., Van Leerdam M.E., Rauws E.A.J., et al. Outcome of peptic ulcer bleeding, nonsteroidal anti-inflammatory drug use and Helicobacter pylori infection. Clin Gastroenterol Hepatol 3 (2005) 859-864
17. García Rodríguez L.A., Cattaruzzi C., Troncon M.G., et al. Risk of hospitalization for upper gastrointestinal tract bleeding associated with ketorolac, other nonsteroidal anti-inflammatory drugs, calcium antagonists, and other antihypertensive drugs. Arch Intern Med 158 (1998) 33-39
18. Henry D., Lim L.L., Garcia Rodriguez L.A., et al. Variability in risk of gastrointestinal complications with individual non-steroidal anti-inflammatory drugs: results of a collaborative meta-analysis. BMJ 312 (1996) 1563-1566
19. Lanas A., Perez-Aisa M.A., Feu F., et al., Investigators of the Asociacion Espanola de Gastroenterologia (AEG). A nationwide study of mortality associated with hospital admission due to severe gastrointestinal events and those associated with non-steroidal anti-inflammatory drug use. Am J Gastroenterol 100 (2005) 1685-1693
20. Lanas A., García Rodriguez L.A., and Polo-Tomás M. Time trends and impact of both upper and lower gastrointestinal bleeding and perforation. Am J Gastroenterol 104 7 (2009) 1633-1641
21. Langman M.J., Cheng K.K., Gilman E.A., et al. Effect of anti-inflammatory drugs on overall risk of common cancer: case-control study in general practice research database. Br Med J 320 (2000) 1642-1646
22. Beard C.M., Waring S.C., O'Brien P.C., et al. Nonsteroidal anti-inflammatory drug use and Alzheimer's disease: a case-control study in Rochester, Minnesota, 1980 through 1984. Mayo Clin Proc 73 (1998) 951-955
23. Moore A., Bjarnason I., Cryer B., et al. Evidence for endoscopic ulcers as meaningful surrogate endpoint for clinically significant upper gastrointestinal harm. Clin Gastroenterol Hepatol (2009) [Epub ahead of print]
24. Yeomans N.D., Lanas A.I., Talley N.J., et al. Prevalence and incidence of gastroduodenal ulcers during treatment with vascular protective doses of aspirin. Aliment Pharmacol Ther 22 (2005) 795-801
25. Holtmann G., Gshossmann J., Buenger L., et al. Do changes in visceral sensory function determine the development of dyspepsia during treatment with aspirin?. Gastroenterology 123 (2002) 1451-1458
26. Lanas A., Bajador E., Serrano P., et al. Nitrovasodilators, low dose aspirin, others nonsteroidal antiinflammatory drugs, and the risk of upper gastrointestinal bleeding. N Engl J Med 343 (2000) 834-839
27. García Rodriguez L.A., Hernandez-Diaz S., and de Abajo F.J. Association between aspirin and upper gastrointestinal complications: systematic review of epidemiologic studies. Br J Clin Pharmacol 52 (2001) 563-571
28. Serensen H.T., Mellemkjaer L., Blot W.J., et al. Risk of upper gastrointestinal bleeding associated with use of low-dose aspirin. Am J Gastroenterol 95 (2000) 2218-2224
29. Ibañez L., Vidal X., Vendrell L., et al. Upper gastrointestinal bleeding associated with antiplatelet drugs. Aliment Pharmacol Ther 23 (2006) 235-242
30. Weil J., Colin-Jones D., Langman M., et al. Prophylactic aspirin and risk of peptic ulcer bleeding. Br Med J 310 (1995) 827-830
31. Hoftiezer J.W., Silvoso G.R., Burks M., et al. Comparison of the effects of regular and enteric-coated aspirin on gastroduodenal mucosa of man. Lancet 2 (1980) 609-612
32. Prichard P.J., Kitchingman G.K., Walt R.P., et al. Human gastric mucosal bleeding induced by low dose aspirin, but not warfarin. Br Med J 298 (1989) 493-496
33. Hawthorne A.B., Mahida Y.R., Cole A.T., et al. Aspirin induced gastric mucosal damage: prevention by enteric-coating and relation to prostaglandin synthesis. Br J Clin Pharmacol 32 (1991) 77-83
34. Kelly J.P., Kaufman D.W., Jurgelon J.M., et al. Risk of aspirin associated major upper-gastrointestinal bleeding with enteric coated or buffered product. Lancet 348 (1996) 1413-1613
35. Serebruany V.L., Steinhubl S.R., Berger P.B., et al. Analysis of risk of bleeding complications after different doses of aspirin in 192 036 patients enrolled in 31 randomized controlled trials. Am J Cardiol 95 (2005) 1218-1222
36. Derry S., and Loke Y.K. Risk of gastrointestinal haemorrhage with long term use of aspirin: meta-analysis. Br Med J 321 (2000) 1183-1187
37. McQuaid K.R., and Laine L. Systematic review and meta-analysis of adverse events of low-dose aspirin and clopidogrel in randomized controlled trials. Am J Med 199 (2006) 624-638
38. Bresalier R.S., Sandler R.S., Quan H., et al., Adenomatous Polyp Prevention on Vioxx (APROVe) Trial Investigators. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 352 11 (2005 Mar 17) 1092-1102 Epub 2005 Feb 15. Erratum in: N Engl J Med. 2006 Jul 13;355(2):221
39. Schnitzer T.J., Burmester G.R., Mysler E., et al. Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: randomised controlled trial. Lancet 364 (2004) 665-674
40. Silverstein F.E., Faich G., Goldstein J.L., et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA 284 (2000) 1247-1255
41. Rostom A., Muir K., Dubé C., et al. Gastrointestinal safety of cyclooxygenase-2 inhibitors: a Cochrane Collaboration systematic review. Clin Gastroenterol Hepatol 5 7 (2007 Jul) 818-828
42. Singh G., Fort J.G., Goldstein J.L., et al. Celecoxib versus naproxen and diclofenac in osteoarthritis patients: SUCCESS-I Study. Am J Med 119 (2006) 255-266
43. Rahme E., Dasgupta K., Toubouti Y., et al. GI effect of rofecoxib and celecoxib versus NSAID in patients on low dose aspirin, a population-based retrospective cohort study. Gastroenterology 126 (2004) A1 [abstract no.17]
44. Teeling M., Bennett K., and Feely J. Have COX-2 inhibitors influenced the co-prescription of anti-ulcer drugs with NSAIDs?. J Clin Pharmacol 57 3 (2004) 337-343
45. Michael P., Maddox T., Wang L., et al. Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome. JAMA 301 9 (2009) 937-944
46. Lanas A., García Rodriguez L.A., Arroyo M.T., et al. Effect of antisecretory drugs and nitrates on the risk of ulcer bleeding associated with nonsteroidal anti-inflammatory drugs, antiplatelet agents, and anticoagulants. Am J Gastroenterol 102 (2007) 507-515
47. De Abajo F.J., and García Rodríguez L.A. Risk of upper gastrointestinal tract bleeding associated with selective serotonin reuptake inhibitors and venlafaxine therapy: interaction with nonsteroidal anti-inflammatory drugs and effect of acid-suppressing agents. Arch Gen Psychiatry 65 7 (2008 Jul) 795-803
48. Opatrny L., Delaney J.A., Suissa S., Division of Clinical Epidemiology, McGil University Health Center, McGill University, Montreal, and Canada. Gastro-intestinal haemorrhage risks of selective serotonin receptor antagonist therapy: a new look. Br J Clin Pharmacol 66 1 (2008 Jul) 76-81 Epub 2008 May 6
49. Lanas A., and Scheiman J. Low dose aspirin and upper gastrointestinal damage: epidemiology, prevention and treatment. Curr Med Res Opin 23 1 (2007 Jan) 163-173
50. Bhatt D.L., Scheiman J., Abraham N.S., et al., American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. J Am Coll Cardiol 52 18 (2008 Oct 28) 1502-1517
51. Andreotti F., Testa L., Biondi-Zoccai G.G., et al. Aspirin plus warfarine compare to aspirin alone after acute coronary syndromes: an updated and comprehensive meta-analysis of 25307 patients. Eur Heart J 27 (2006) 519-526
52. Atherton C., Jones J., McKaig B., et al. Pharmacology and gastrointestinal safety of lumiracoxib, a novel cyclooxygenase-2 selective inhibitor: an integrated study. Clin Gastroenterol Hepatol 2 (2004) 113-120
53. Twiss I.M., Burggraaf J., Schoemaker R.C., et al. The sugar absorption test in the evaluation of the gastrointestinal intolerant to bisphosphonates: studies with oral pamidronate. Clin Pharmacol Ther 69 (2001) 431-437
54. Sigthorsson G., Crane R., Simon T., et al. COX-2 inhibition with rofecoxib does not increase intestinal permeability in healthy subjects: a double blind crossover study comparing rofecoxib with placebo and indomethacin. Gut 47 (2000) 527-532
55. Smecuol E., Bai J.C., Sugai E., et al. Acute gastrointestinal permeability responses to different non-steroidal anti-inflammatory drugs. Gut 49 (2001) 650-655
56. Bjarnason I., Williams P., Smethurst P., et al. Effect of non-steroidal anti-inflammatory drugs and prostaglandins on the permeability of the human small intestine. Gut 27 (1986) 1292-1297
57. Jenkins A.P., Trew D.R., Crump B.J., et al. Do non-steroidal anti-inflammatory drugs increase colonic permeability?. Gut 32 (1991) 66-69
58. Day J.P., Lanas A., Rustagi P., et al. Reversible prolonged skin bleeding time in acute gastrointestinal bleeding presumed due to NSAIDs. J Clin Gastroenterol 22 (1996) 96-103
59. Smecuol E., Pinto M.I., Suarez A., et al. Low-dose aspirin affects the small bowel mucosa: results of a pilot study with a multidimensional assessment. Clin Gastroenterol Hepatol 7 5 (2009) 524-529
60. Goldstein J.L., Eisen G.M., Lewis B., et al. Video capsule endoscopy to prospectively assesses small bowel injury with celecoxib, naproxen plus omeprazole, and placebo. Clin Gastroenterol Hepatol 3 2 (2005) 133-141
61. Laine L., Smith R., Min K., et al. Systematic review: the lower gastrointestinal adverse effects of non-steroidal anti-inflammatory drugs. Aliment Pharmacol Ther 24 (2006) 751-767
62. Lanas A., Panes J., and Pique J.M. Clinical implications of COX-1 and/or COX-2 inhibition for the distal gastrointestinal tract. Curr Pharm Des 9 (2003) 2253-2266
63. Hunt R.H., Bowen B., Mortensen E.R., et al. A randomized trial measuring fecal blood loss after treatment with rofecoxib, ibuprofen, or lacebo in healthy subjects. Am J Med 109 (2000) 201-206
64. Hawkey C., Smalley W., Ehrsam E., et al. Therapeutic arthritis research and gastrointestinal event trial (TARGET) of lumiracoxib vs naproxen and ibuporfen: incidence of anemia. Gastroenterology 128 (2005) W1567
65. Lanas A., Serrano P., Bajador E., et al. Evidence of aspirin use in both upper and lower gastrointestinal perforation. Gastroenterology 112 (1997) 683-689
66. Wilcox C.M., Alexander L.N., Cotsonis G.A., et al. Nonsteroidal anti-inflammatory drugs are associated with both upper and lower gastrointestinal bleeding. Dig Dis Sci 42 (1997) 990-997
67. Shah A.A., Thjodleifsson B., Murray F.E., et al. Selective inhibition of COX-2 in humans is associated with less gastrointestinal injury: a comparison of nimesulide and naproxen. Gut 48 (2001) 339-346
68. Langman M.J., Morgan L., and Worrall A. Use of anti-inflammatory drugs by patients admitted with small or large bowel perforations and haemorrhage. Br Med J (Clin Res Ed) 290 (1985) 347-349
69. Lanas A., Sekar M.C., and Hirschowitz B.I. Objective evidence of aspirin use in both ulcer and non-ulcer upper and lower gastrointestinal bleeding. Gastroenterology 103 (1992) 862-869
70. Aldoori W.H., Giovannucci E.L., Rimm E.B., et al. Use of acetaminophen and nonsteroidal anti-inflammatory drugs: a prospective study and the risk of symptomatic diverticular disease in men. Arch Fam Med 7 (1998) 255-260
71. Morris C.R., Harvey I.M., Stebbings W.S., et al. Anti-inflammatory drugs, analgesics and the risk of perforated colonia diverticular disease. Br J Surg 90 (2003) 1267-1272
72. Laine L., Curtis S.P., Cryer B., et al. Assessment of upper gastrointestinal safety of Etorycoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etorycoxib and Diclofenac Arthrtis long therm (MEDAL) program: a randomised comparison. Lancet 369 9560 (2007 Feb 10) 465-473
73. Pilotto A., Franceschi M., Vitale D., et al. The prevalence of diarrhea and its association with drug use in elderly outpatients: a multicenter study. Am J Gastroenterol 103 11 (2008) 2816-2823
74. Rostom A., Wells G., Tugwell P., et al. Prevention of chronic NSAID induced upper gastrointestinal toxicity. Cochrane Database Syst Rev 3 (2000) CD002296
75. Hudson N., Taha A.S., Russell R.I., et al. Famotidine for and maintenance in nonsteroidal anti-inflammatory drug-associated gastroduodenal ulceration. Gastroenterology 6 (1997) 1817-1822
76. Yeomans N.D., Tulassay Z., Juhász L., et al. A comparison of omeprazole with ranitidine for ulcers associated with nonsteroidal antiinflammatory drugs. Acid Suppression Trial: Ranitidine versus Omeprazole for NSAID-associated Ulcer Treatment (ASTRONAUT) Study Group. N Engl J Med 338 11 (1998 Mar 12) 719-726
77. Hawkey C.J., Karrasch J.A., Szczepañski L., et al. Omeprazole compared with misoprostol for ulcers associated with nonsteroidal anti-inflammatory drugs. Omeprazole versus Misoprostol for NSAID-induced Ulcer Management (OMNIUM) Study Group. N Engl J Med 338 11 (1998 Mar 12) 727-734
78. Laheij R.J., Sturkenboom M.C., Hassing R.J., et al. Risk of community-acquired pneumonia and use of gastric acid-suppressive drugs. JAMA 292 (2004) 1955-1960
79. Canadian Coordinating Office for Health Technology Assessment. Gastroduodenal ulcers associated with the use of non-steroidal anti-inflammatory drugs: a systematic review of preventive pharmacological interventions (2004 Feb), Canadian Coordinating Office for Health Technology Assessment, Ottawa Report no. 12
80. Hawkey C.J. Nonsteroidal anti-inflammatory drug gastropathy. Gastroenterology 119 (2000 Aug) 521-535
81. Chan F.K., Hung L.C., Suen B.Y., et al. Celecoxib diclofenac and omeprazole in reducing the risk of recurrent ulcer bleeding in patients with arthritis. N Engl J Med 347 26 (2002) 2104-2110
82. Lai K.C., Chu K.M., Hui W.M., et al. Celecoxib compared with lansoprazole and naproxen to prevent gastrointestinal ulcer complications. Am J Med 118 11 (2005) 1271-1278
83. Chan F.K., Chung S.C., Suen B.Y., et al. Preventing recurrent upper gastrointestinal bleeding in patients with Helicobacter pylori infection who are taking low-dose aspirin or naproxen. N Engl J Med 334 13 (2001 Mar 29) 967-973
84. Chan F.K., Wong V.W., Suen B.Y., et al. Combination of a cyclo-oxygenase-2 inhibitor and a proton-pump inhibitor for prevention of recurrent ulcer bleeding in patients at very high risk: a double-blind, randomised trial. Lancet 369 9573 (2007 May 12) 1621-1626
85. Watson D.J., Harper S.E., Zhao P.L., et al. Gastrointestinal tolerability of the selective cyclooxygenase-2 (COX-2) inhibitor rofecoxib compared with nonselective COX-1 and COX-2 inhibitors in osteoarthritis. Arch Intern Med 160 (2000) 2998-3003
86. Mc Gettigan P., and Henry D. Cardiovascular risk and inhibition of cyclooxygenase: a systematic review of the observational studies of selective and non selective inhibitors of cyclooxygenase 2. JAMA 296 13 (2006 Oct 4) 1633-1644
87. Watanabe T., Sugimori S., Kameda N., et al. Small bowel injury by low dose enteric-coated aspirin and treatment with misoprostol: a pilot study. Clin Gastroenterol Hepatol 6 11 (2008 Nov) 1279-1282
88. Lanas A., and Scarpignato C. Microbial flora in NSAID-induced intestinal damage: a role for antibiotics?. Digestion 73 Suppl. 1 (2006) 136-150
89. Lanas A., Fuentes J., Benito R., et al. Helicobacter pylori increases the risk of upper gastrointestinal bleeding in patients taking low-dose aspirin. Aliment Pharmacol Ther 16 (2002) 779-786
90. Serrrano P., Lanas A., Arroyo M., et al. Risk stratification of upper gastrointestinal bleeding in cardiovascular patients on low dose aspirin: a cohort study. Aliment Pharmacol Ther 16 11 (2002 Nov) 1945-1953
91. Chan F.K. Management of high risk patients on non-steroidal antiinflammatory drugs or aspirin. Drugs 66 Suppl. 1 (2006) 23-28
92. Chan F.K., and Graham D.Y. Review article: prevention of non-steroidal anti-inflammatory drug gastrointestinal complications-review and recommendations based on risk assessment. Aliment Pharmacol Ther 19 10 (2004 May 15) 1051-1061
93. Lai K.C., Lam S.K., Chu K.M., et al. Lansoprazole for the prevention of recurrences of ulcer complications from long-term low-dose aspirin use. N Engl J Med 346 26 (2002 Jun 27) 2033-2038